These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23775007)

  • 1. Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial.
    Tang WH; Lin FH; Lee CH; Kuo FC; Hsieh CH; Hsiao FC; Hung YJ
    Endocrine; 2014 Mar; 45(2):293-301. PubMed ID: 23775007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cilostazol attenuates the severity of peripheral arterial occlusive disease in patients with type 2 diabetes: the role of plasma soluble receptor for advanced glycation end-products.
    Liu JS; Chuang TJ; Chen JH; Lee CH; Hsieh CH; Lin TK; Hsiao FC; Hung YJ
    Endocrine; 2015 Aug; 49(3):703-10. PubMed ID: 25666934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease.
    O'Donnell ME; Badger SA; Sharif MA; Makar RR; McEneny J; Young IS; Lee B; Soong CV
    Eur J Vasc Endovasc Surg; 2009 Mar; 37(3):326-35. PubMed ID: 19112032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial.
    Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Okuda Y; Sawanobori T
    Clin J Am Soc Nephrol; 2020 Dec; 15(12):1715-1727. PubMed ID: 33239409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients.
    Agrawal NK; Maiti R; Dash D; Pandey BL
    Pharmacol Res; 2007 Aug; 56(2):118-23. PubMed ID: 17548203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.
    De Jager J; Kooy A; Lehert P; Bets D; Wulffelé MG; Teerlink T; Scheffer PG; Schalkwijk CG; Donker AJ; Stehouwer CD
    J Intern Med; 2005 Jan; 257(1):100-9. PubMed ID: 15606381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intervention with cilostazol attenuates renal inflammation in streptozotocin-induced diabetic rats.
    Wang F; Li M; Cheng L; Zhang T; Hu J; Cao M; Zhao J; Guo R; Gao L; Zhang X
    Life Sci; 2008 Dec; 83(25-26):828-35. PubMed ID: 18983856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria.
    Menne J; Eulberg D; Beyer D; Baumann M; Saudek F; Valkusz Z; Więcek A; Haller H;
    Nephrol Dial Transplant; 2017 Feb; 32(2):307-315. PubMed ID: 28186566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study.
    Persson F; Rossing P; Hovind P; Stehouwer CD; Schalkwijk CG; Tarnow L; Parving HH
    Scand J Clin Lab Invest; 2008; 68(8):731-8. PubMed ID: 18609080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cilostazol inhibits cytokine-induced nuclear factor-kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells.
    Hattori Y; Suzuki K; Tomizawa A; Hirama N; Okayasu T; Hattori S; Satoh H; Akimoto K; Kasai K
    Cardiovasc Res; 2009 Jan; 81(1):133-9. PubMed ID: 18703532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying patients with type 2 diabetes at high risk of microalbuminuria: results of the DEMAND (Developing Education on Microalbuminuria for Awareness of reNal and cardiovascular risk in Diabetes) Study.
    Rossi MC; Nicolucci A; Pellegrini F; Comaschi M; Ceriello A; Cucinotta D; Giorda C; Valentini U; Vespasiani G; De Cosmo S
    Nephrol Dial Transplant; 2008 Apr; 23(4):1278-84. PubMed ID: 18039647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.
    de Zeeuw D; Renfurm RW; Bakris G; Rossing P; Perkovic V; Hou FF; Nangaku M; Sharma K; Heerspink HJL; Garcia-Hernandez A; Larsson TE
    Lancet Diabetes Endocrinol; 2018 Dec; 6(12):925-933. PubMed ID: 30413396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.
    Elajami TK; Alfaddagh A; Lakshminarayan D; Soliman M; Chandnani M; Welty FK
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28710178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cilostazol suppression of arterial intimal hyperplasia is associated with decreased expression of sialyl Lewis X homing receptors on mononuclear cells and E-selectin in endothelial cells.
    Takigawa T; Tsurushima H; Suzuki K; Tsuruta W; Nakamura K; Matsumura A
    J Vasc Surg; 2012 Feb; 55(2):506-16. PubMed ID: 22264805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy.
    Katayama S; Yamada D; Nakayama M; Yamada T; Myoishi M; Kato M; Nowack C; Kolkhof P; Yamasaki Y;
    J Diabetes Complications; 2017 Apr; 31(4):758-765. PubMed ID: 28025025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of cilostazol on carotid intima-media thickness in type 2 diabetic patients without cardiovascular event.
    Huh JH; Seok H; Lee BW; Kang ES; Lee HC; Cha BS
    Endocrine; 2014 Sep; 47(1):138-45. PubMed ID: 24381128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: A randomized controlled trial.
    Agha A; Amer W; Anwar E; Bashir K
    Saudi J Kidney Dis Transpl; 2009 May; 20(3):429-35. PubMed ID: 19414946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tocotrienol-Rich Vitamin E from Palm Oil (Tocovid) and Its Effects in Diabetes and Diabetic Nephropathy: A Pilot Phase II Clinical Trial.
    Tan SMQ; Chiew Y; Ahmad B; Kadir KA
    Nutrients; 2018 Sep; 10(9):. PubMed ID: 30227659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial.
    Mosenzon O; Leibowitz G; Bhatt DL; Cahn A; Hirshberg B; Wei C; Im K; Rozenberg A; Yanuv I; Stahre C; Ray KK; Iqbal N; Braunwald E; Scirica BM; Raz I
    Diabetes Care; 2017 Jan; 40(1):69-76. PubMed ID: 27797925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.